Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

3.22
-0.2095-6.11%
Volume:37.66K
Turnover:128.49K
Market Cap:5.91M
PE:-0.12
High:3.60
Open:3.60
Low:3.21
Close:3.43
52wk High:36.65
52wk Low:1.50
Shares:1.84M
Float Shares:1.65M
Volume Ratio:0.58
T/O Rate:2.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-27.1846
EPS(LYR):-63.7804
ROE:-151.36%
ROA:-13.88%
PB:0.80
PE(LYR):-0.05

Loading ...

Aug 28, 2026

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Aug 20, 2026

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Aug 14, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 14, 2026

Major Issues Report

Form 8-K - Current report
Aug 14, 2026

[Rev.]Quaterly Report

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
Aug 14, 2026

Major Issues Report

Form 8-K - Current report
Jul 30, 2026

Major Issues Report

Form 8-K - Current report
Jul 01, 2026

Major Issues Report

Form 8-K - Current report
Jun 30, 2026

Major Issues Report

Form 8-K - Current report
Jun 26, 2026

Major Issues Report

Form 8-K - Current report
Jun 18, 2026

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Jun 16, 2026

Major Issues Report

Form 8-K - Current report
Jun 16, 2026

Major Issues Report

Form 8-K - Current report
Jun 08, 2026

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Jun 01, 2026

Major Issues Report

Form 8-K - Current report
May 27, 2026

Major Issues Report

Form 8-K - Current report
May 21, 2026

Major Issues Report

Form 8-K - Current report
May 15, 2026

Beneficial Ownership Change

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
May 14, 2026

Major Issues Report

Form 8-K - Current report
May 14, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]